Humira approved for juvenile rheumatoid arthritis

Article

Abbott's Humira (adalimumab) had been approved by the food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis...

Abbott's Humira (adalimumab) has been approved by the Food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis.

JVA joins other indications including chronic plaque psoriasis, rheumatoid arthritis in adults, and Crohn's disease.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Russell Libby, MD, FAAP
Lawrence Eichenfield, MD
Wendy Ripple, MD
Wendy Ripple, MD
Lawrence Eichenfield, MD
Related Content
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes E. Gonzalez, MD
June 27th 2025
Article

Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

stock image of a hemangioma

Recognize & Refer: Hemangiomas in pediatrics

Lisette Hilton
July 17th 2019
Podcast

Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.

FDA extends review of ruxolitinib cream for pediatric atopic dermatitis | Image credit: Contemporary Pediatrics.

FDA extends review of ruxolitinib cream for pediatric atopic dermatitis

Morgan Ebert, Managing Editor
June 20th 2025
Article

The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.

Treating Patients with Trichotillomania and Other Related Behaviors

Treating Patients with Trichotillomania and Other Related Behaviors

Jon E. Grant, JD, MD, MPH
September 13th 2011
Podcast

Dr Jon E. Grant talks about the genetics, neurobiology, and cognitive processes of body-focused repetitive behaviors, which include trichotillomania, skin picking, and other behaviors.

Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

Joshua Fitch, Senior Editor
June 13th 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

First infant enrolled in trial of roflumilast 0.05% for atopic dermatitis in infants | | Image Credit: © Dinko - © Dinko- stock.adobe.com.

First infant enrolled in trial of roflumilast cream, 0.05% for atopic dermatitis in infants

Joshua Fitch, Senior Editor
June 10th 2025
Article

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.

© 2025 MJH Life Sciences

All rights reserved.